Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOH8LD)

• Drug Name: Senktide Drug Info
• Synonyms: Senktide; CHEMBL106124; Succinyl-6-asp-8-Me-phe-substance P (6-11); Substance P (6-11), succinyl-asp(6)-Me-phe(8)-; Substance P (6-11), succinyl-aspartyl(6)-methylphenylalanine(8)-; L-Methioninamide, N-(3-carboxy-1-oxopropyl)-L-alpha-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl-

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Phase 2	[1]
Ischemic stroke	8B11.5Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 108147
  CAS Number: CAS 106128-89-6
  TTD Drug ID: DMOH8LD

Molecule-Related Drug Atlas

Drug(s) Targeting Neuromedin-K receptor (TACR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fezolinetant	DMHDQZD	Hot flushes	GA30	Approved	[4]
Elinzanetant	DMC6EFI	Hot flushes	GA30	Phase 3	[5]
AZD2624	DMZLGQV	Multiple sclerosis	8A40	Phase 2	[6]
Talnetant	DMQKZDT	Schizophrenia	6A20	Phase 2	[7]
GSK1144814	DMK3S9J	Alcohol dependence	6C40.2	Phase 1	[8]
Osanetant	DMMT4PB	Schizoaffective disorder	6A21	Discontinued in Phase 2b	[7]
CS-003	DM1AEVT	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[9]
SSR-146977	DMR9JA8	Psychotic disorder	6A20-6A25	Discontinued in Phase 1	[10]
SB222200	DM6X0PZ	Schizoaffective disorder	6A21	Preclinical	[11]
neurokinin A	DM9UXRP	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Integrin alpha-4 (ITGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vedolizmab	DMV3YMX	Crohn disease	DD70	Approved	[13]
Antegren	DMNC64R	Multiple sclerosis	8A40	Approved	[14]
Natalizumab	DMAK85L	Crohn disease	DD70	Approved	[15]
PB006	DMVHGLA	Crohn disease	DD70	Phase 3	[16]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[17]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[18]
BIO-1211	DMKICA3	Asthma	CA23	Phase 2	[19]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[18]
ELND-002	DMM9S51	Autoimmune diabetes	5A10	Phase 1	[20]
ELND-004	DMLQYVD	Autoimmune diabetes	5A10	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4 (ITGA4)	TT4BT06	ITA4_HUMAN	Inhibitor	[2]
Neuromedin-K receptor (TACR3)	TTBPGLU	NK3R_HUMAN	Agonist	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
• [4] Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102.
• [5] Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
• [6] The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204.
• [7] Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
• [8] Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
• [9] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [10] Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol. 2002 May;80(5):482-8.
• [11] Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24.
• [12] Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.
• [13] Clinical pipeline report, company report or official report of Takeda (2009).
• [14] Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
• [15] Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
• [16] Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
• [17] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
• [20] Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.